Ranđelović Marina, Dimitrijević Marina, Mijatović Stefan, Ignjatović Aleksandra, Arsić-Arsenijević Valentina, Stojanović-Radić Zorica, Hay Roderick, Otašević Suzana
Department of Microbiology and Immunology, Medical Faculty, University of Niš, Boulevard Dr Zorana Đinđića 81, Niš, 18000, Serbia.
Centre of Microbiology, Public Health Institute Niš, Boulevard Dr Zorana Đinđića 50, Niš, 18000, Serbia.
Braz J Microbiol. 2024 Dec;55(4):3863-3872. doi: 10.1007/s42770-024-01529-1. Epub 2024 Oct 1.
Recurrent vulvovaginal candidosis (RVVC) is a chronic infection affecting 8-10% of women worldwide. Biofilm production of the infecting species and reduced sensitivity to antimycotics could contribute to the recurrence of this infection. This study aimed to examine the biofilm production ability and antifungal susceptibility of genital yeast isolates to determine their virulence potential.
Matrix-assisted laser desorption in ionization-time of flight mass spectrometry (MALDI-TOF MS) was used to identify 300 Candida species. Using crystal violet method, strains were categorized into non-producers, weak, moderate, and strong biofilm producers (BFP). Antifungal susceptibility testing was performed using commercial Integral System YEASTS Plus test (ISYPT) and broth microdilution method (BMM).
MALDI-TOF MS identified 150 Candida albicans, 124 non-albicans Candida (NAC), and 26 Saccharomyces cerevisiae strains. Within 138 (46.0%) BFP, 23 (16.7%) were strong, 44 (31.9%) moderate, and 71 (51.4%) weak. BMM was done for 43 BFP selected isolates with nystatin MIC ˃1.25 μl, fluconazole MIC ˃64 μl, and clotrimazole MIC ˃1.0 μl determined by ISYPT. Compared to all examined isolates, BMM confirmed that: i) C. albicans and NAC BFP showed low sensitivity to fluconazole (12% and 4%, respectively); ii) all BFP showed low sensitivity to nystatin (12.7% C. albicans, 14.5% NAC, and 23.1% S. cerevisiae); iii) clotrimazole in vitro was the most efficient regarding C. albicans and S. cerevisiae strains, but in 4.0% NAC BFP for this antimycotic higher MIC was established.
Novel antimycotics or possible combinations of antifungal agents and natural products could be a new treatment option for RVVC.
复发性外阴阴道念珠菌病（RVVC）是一种慢性感染，影响着全球8%至10%的女性。感染菌种的生物膜形成以及对抗真菌药物敏感性的降低可能导致这种感染的复发。本研究旨在检测生殖道酵母菌分离株的生物膜形成能力和抗真菌药敏性，以确定其毒力潜力。
采用基质辅助激光解吸电离飞行时间质谱（MALDI-TOF MS）鉴定300株念珠菌属菌种。使用结晶紫法将菌株分为非生物膜形成菌、弱生物膜形成菌、中度生物膜形成菌和强生物膜形成菌（BFP）。采用商业一体化系统酵母菌加样试验（ISYPT）和肉汤微量稀释法（BMM）进行抗真菌药敏试验。
MALDI-TOF MS鉴定出150株白色念珠菌、124株非白色念珠菌（NAC）和26株酿酒酵母菌株。在138株（46.0%）BFP中，23株（16.7%）为强生物膜形成菌，44株（31.9%）为中度生物膜形成菌，71株（51.4%）为弱生物膜形成菌。对43株通过ISYPT测定的制霉菌素MIC＞1.25μl、氟康唑MIC＞64μl和克霉唑MIC＞1.0μl的BFP选择分离株进行了BMM。与所有检测的分离株相比，BMM证实：i）白色念珠菌和NAC BFP对氟康唑敏感性较低（分别为12%和4%）；ii）所有BFP对制霉菌素敏感性较低（白色念珠菌为12.7%，NAC为14.5%，酿酒酵母为23.1%）；iii）克霉唑在体外对白色念珠菌和酿酒酵母菌株最有效，但在4.0%的NAC BFP中，该抗真菌药的MIC较高。
新型抗真菌药物或抗真菌药物与天然产物的可能组合可能是RVVC的一种新治疗选择。
